Mirum Pharmaceuticals
NEWS
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
The rolling NDA was somewhat expected after an end-of-phase meeting with the FDA earlier this year turned into a pre-NDA meeting with the regulatory agency.
Mirum Pharmaceuticals entered 2020 with a significant bounce after the U.S. Food and Drug Administration turned an end-of-phase meeting into a pre-New Drug Application meeting for its lead asset, maralixibat, an investigational treatment being evaluated for pediatric patients with Alagille syndrome.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Life sciences and pharma companies strengthen their leadership teams and board with this week’s Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Companies strengthen their leadership teams and boards of directors with this week’s slate of Movers & Shakers.
JOBS
IN THE PRESS